BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 1350129)

  • 1. [C-erbB-2 oncogene amplification in breast cancer in correlation to steroid and epidermal growth factor receptor].
    Manavi M; Czerwenka KF; Zeillinger R; Speiser P; Kury F; Steinhart U; Peschke M; Kubista E; Reinold E
    Zentralbl Gynakol; 1992; 114(2):82-5. PubMed ID: 1350129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Use of polymerase chain reaction (PCR) as an additional diagnostic method in gynecologic oncology].
    Czerwenka KF; Zeillinger R; Kury F; Manavi M; Speiser P; Peschke M; Steinhart U; Hosmann JW; Kubista E
    Gynakol Rundsch; 1991; 31 Suppl 2():378-9. PubMed ID: 1686430
    [No Abstract]   [Full Text] [Related]  

  • 3. Correlation of c-erbB-2 protein expression with histologic grade, lymph node involvement and steroid receptor status in human breast tumors.
    Lampe B; Genz T; Maassen V; Mikorey S; Klosterhalfen T
    Arch Gynecol Obstet; 1992; 251(1):45-50. PubMed ID: 1347986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma.
    Tavassoli M; Quirke P; Farzaneh F; Lock NJ; Mayne LV; Kirkham N
    Br J Cancer; 1989 Oct; 60(4):505-10. PubMed ID: 2572268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade.
    Tsuda H; Iwaya K; Fukutomi T; Hirohashi S
    Jpn J Cancer Res; 1993 Apr; 84(4):394-401. PubMed ID: 8099903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
    Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
    Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression.
    Mandai M; Konishi I; Koshiyama M; Mori T; Arao S; Tashiro H; Okamura H; Nomura H; Hiai H; Fukumoto M
    Cancer Res; 1994 Apr; 54(7):1825-30. PubMed ID: 7907945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Oncogene organization and expression in breast cancer exemplified by proto-oncogene c-erb B2].
    Friedrichs K; Jonat W; Meybohm J; Singh S
    Arch Gynecol Obstet; 1989; 245(1-4):658-60. PubMed ID: 2572202
    [No Abstract]   [Full Text] [Related]  

  • 9. p185 overexpression in 220 samples of breast cancer undergoing primary surgery: comparison with c-erbB-2 gene amplification.
    Dalifard I; Daver A; Goussard J; Lorimier G; Gosse-Brun S; Lortholary A; Larra F
    Int J Mol Med; 1998 May; 1(5):855-61. PubMed ID: 9852307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of the p185neu oncoprotein indicates an unfavorable prognosis in small, node negative breast cancer without systemic adjuvant treatment (T1N0)].
    Göhring UJ; Aslan-Schadwinkel Y; Scharl A
    Geburtshilfe Frauenheilkd; 1993 Sep; 53(9):625-9. PubMed ID: 7901111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of erbB-2 gene amplification with low levels of estrogen and/or progesterone receptors in primary breast cancer: do erbB-2 products delineate hormone-independent tumors?
    Roux-Dosseto M; Romain S; Dussault N; Martin PM
    Biomed Pharmacother; 1989; 43(9):641-9. PubMed ID: 2696563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. With special reference to their prognostic significance in carcinoma.
    Tauchi K; Hori S; Itoh H; Osamura RY; Tokuda Y; Tajima T
    Virchows Arch A Pathol Anat Histopathol; 1989; 416(1):65-73. PubMed ID: 2573192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical evaluation of ErbB-2 protein in tissue extract using an enzyme immuno assay (ErbB-2 EIA "Nichirei")].
    Sugano K; Kitajima M; Ishii M; Koyama H; Kasumi F; Demura R; Mori S; Ohkura H
    Gan To Kagaku Ryoho; 1994 Sep; 21(12):1957-66. PubMed ID: 7916182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease.
    Dawkins HJ; Robbins PD; Smith KL; Sarna M; Harvey JM; Sterrett GF; Papadimitriou JM
    Pathol Res Pract; 1993 Dec; 189(10):1233-52. PubMed ID: 7910395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Incidence of amplification of the C-erb B2/Her-2/neu gene in human breast cancer].
    Sellami M; Gamoudi M; Krichen K; Kharrat A; Ben Romdhane K; Maalej M
    Arch Inst Pasteur Tunis; 1991; 68(1-2):33-41. PubMed ID: 1687309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer.
    Le Roy X; Escot C; Brouillet JP; Theillet C; Maudelonde T; Simony-Lafontaine J; Pujol H; Rochefort H
    Oncogene; 1991 Mar; 6(3):431-7. PubMed ID: 1707153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
    Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
    Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of EGFR, c-erbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer.
    Hainsworth PJ; Henderson MA; Stillwell RG; Bennett RC
    Eur J Surg Oncol; 1991 Feb; 17(1):9-15. PubMed ID: 1671658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
    McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN
    Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
    Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
    Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.